CNW/ - Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by public drug programs in Ontario, ...

CNW/ - Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by Régie de l'assurance maladie du ...

Regeneron Pharmaceuticals (REGN) just moved a step closer to expanding its cancer therapy portfolio in Europe after the ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy Right Now. On October 17 ...

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

Q3 2025 Earnings Call Transcript October 28, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS ...

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Discover Regeneron’s Q3 2025 earnings: strong Dupixent, Libtayo & EYLEA HD growth, R&D updates, plus key manufacturing and regulatory challenges.

Third quarter 2025 revenues increased 1% to $3.75 billion versus third quarter 2024Dupixent® global net sales(recorded by Sanofi) increased 27% ...

Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q3 CY2025, but sales were ...

Regeneron investors should embrace the fact that Eylea is no longer a growth product and focus on the rest of the commercial ...